CD274 and non-small cell lung carcinoma: In a phase 3 OAK trial, atezolizumab (anti-PD-L1 antibody) treatment prolonged overall survival compared with docetaxel in previously treated patients with non-small cell lung cancer, regardless of PD-L1 expression status (3).